The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …

COVID antiviral pills: what scientists still want to know IDEAS home Advanced search
Economic literature: papers, articles, software, chapters, books. Authors Institutions …

Coronavirus disease 2019 (COVID-19) is a fatal respiratory illness caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The identification of potential drugs is …

GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted
adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral …

The rapid development of effective vaccines to combat the SARS-CoV-2 virus has been an
effective counter measure to decrease hospitalization and the mortality rate in many …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a global public
health crisis, for which antiviral treatments are considered mainstream therapeutic …

Introduction. The emergence of SARS-CoV-2 has taken humanity off guard. Following an
outbreak of SARS-CoV in 2002, and MERS-CoV about 10 years later, SARS-CoV-2 is the …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Substantial progresshas been made in therapeutics for nonhospitalizedpatientswithCOVID-
19, butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …